As of July 1, Medicare is providing coverage for GLP-1 medications used for weight loss with a $50 co-pay, a move that could make these widely discussed drugs accessible to millions more Americans. Dubbed the Medicare GLP-1 Bridge Program, this one-year pilot project was authorized under the Trump administration. Previously, Medicare’s coverage for GLP-1 drugs was restricted to individuals with diabetes, heart disease, or obstructive sleep apnea.
Under the new program, Medicare enrollees can receive one of three specific drugs—Foundayo, Wegovy, or Zepbound—for weight loss. Eligibility typically requires a body mass index (BMI) of 35 or higher, or a BMI of 27 or higher with specific health conditions. This expansion is poised to be a pivotal moment for the GLP-1 class of drugs, which has already garnered substantial attention and interest, with potential implications for both public health and the broader economy.
Alison Furman, partner and U.S. consumer markets industry leader at PwC, described the drug's impact as a "physiological disruption akin to technological disruptions." She noted that just as smartphones unforeseenly spawned industries like Uber and Netflix, GLP-1 drugs are expected to create a new ecosystem with emerging brands and services.
Data from PwC indicates a doubling in the percentage of households with a GLP-1 user between January 2025 and May 2026, even before the Bridge program's launch. Current trends suggest this program will accelerate these existing patterns. In August 2025, approximately 12 percent of Americans, equating to over 40 million individuals, reported having taken a GLP-1 drug. By May 2026, one in five U.S. households included at least one GLP-1 user, according to PwC data.
The Medicare Bridge program is expected to draw millions more into this trend. Estimates suggest that up to 14 million individuals within the Medicare population are overweight or obese. A more specific KFF analysis, applying the Bridge program's criteria, indicated that about four million beneficiaries could qualify for the $50-per-month GLP-1 offer.
Clinics are anticipating a significant surge in patient demand following the program's rollout, with concerns of being overwhelmed. This event is projected to be one of the largest prescription drug rollouts in history.
Beyond Medicare, pharmaceutical companies are also expanding coverage through private employer-based insurance plans. Laura Steele, group vice president of U.S. cardiometabolic health at Eli Lilly, reported a substantial increase in employer coverage, rising from about 20 percent to 67 percent. Manufacturers are also actively marketing directly to consumers at reduced cash prices, a strategy also employed by direct-to-consumer healthcare businesses.
Despite increased access, cost remains a significant barrier. A November 2025 KFF survey found that over half of GLP-1 users found the drugs unaffordable, and 14 percent had stopped taking them due to cost. As affordability improves, adoption could continue to grow exponentially, especially considering that roughly three-fourths of U.S. adults are overweight or obese. Furman projects that between 50 and 75 percent of Americans could be using these medications within the next decade.
Expanded use of GLP-1 drugs may also help reduce the stigma associated with their use. While some users report facing judgment, data suggests this stigma is diminishing. PwC data shows 23 percent of current GLP-1 users openly discuss their usage, compared to 2 percent who remain entirely secretive. Individuals considering these drugs, potentially influenced by the Medicare Bridge program, appear even more open to sharing their use, with over half indicating they would inform immediate family members.
As GLP-1 usage becomes more widespread, the economic ripple effects are expected to intensify. A PwC consumer survey revealed significant shifts in spending habits among users. More than half reported reduced spending on sugary and salty snacks, 43 percent bought fewer sugary beverages, and 12 percent consumed less alcohol. Concurrently, users increased spending on fresh produce (45 percent), protein-packed snacks (35 percent), and high-fiber foods (28 percent).
The restaurant industry may also see changes, with a 22 percent drop in spending on pizza among GLP-1 households, and reduced spending on takeout chicken, coffee and bakery items, burgers, and deli sandwiches. Furman observed that as people eat less, they tend to prioritize quality over quantity.
Spending patterns extend beyond food, with users reporting a 10 percent increase in apparel purchases, including jeans, swimwear, dresses, and jewelry, within six to eight months of starting the medication. Furthermore, some research suggests a potential link between GLP-1 use and improved job prospects for women, though further study is needed.
The widespread adoption of these weight-loss medications, potentially impacting over half the U.S. population, is anticipated to bring about significant societal and economic transformations, possibly leading to a demarcation of the U.S. economy into pre- and post-GLP-1 eras.